US medical devices industry saw a drop of 35.37% in overall deal activity during January 2021, when compared with the last 12-month average, led by OptumInsight’s $13bn acquisition of Change Healthcare, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 53 deals worth $22.2bn were announced in January 2021, compared with the 12-month average of 82 deals.
M&A was the leading category in the month in terms of volume with 25 deals, which accounted for 47.2% of all deals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was venture financing with 24 deals, followed by private equity with four transactions, respectively accounting for 45.3% and 7.6% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $21.21bn, while venture financing and private equity deals totalled $929.33m and $64m respectively.
US medical devices industry deals in January 2021: Top deals
The top five medical devices industry deals accounted for 90.1% of the overall value during January 2021.
The combined value of the top five medical devices deals stood at $20.01bn, against the overall value of $22.2bn recorded for the month.
The top five medical devices industry deals of January 2021 tracked by GlobalData were:
1) OptumInsight’s $13bn acquisition of Change Healthcare
2) The $4.6bn acquisition of Cantel Medical by Steris
3) Boston Scientific’s $1.23bn acquisition of Preventice
4) The $635m acquisition deal with Capsule Technologies by Koninklijke Philips
5) Thermo Fisher Scientific’s acquisition of Mesa Biotech for $550m.
